title: Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.
authors.affiliation: National Cancer Institute, Bethesda, MD maeve.mullooly@nih.gov.
authors.forename: Maeve
authors.initials: M
authors.lastname: Mullooly
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Pfeiffer
authors.affiliation: University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC.
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Nyante
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Brandy M
authors.initials: BM
authors.lastname: Heckman-Stoddard
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Perloff
authors.affiliation: University of Texas Health Science Center, San Antonio, TX.
authors.forename: Ismail
authors.initials: I
authors.lastname: Jatoi
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Louise A
authors.initials: LA
authors.lastname: Brinton
authors.affiliation: Group Health Research Institute, Seattle, WA.
authors.forename: Erin J
authors.initials: EJ
authors.lastname: Aiello Bowles
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Robert N
authors.initials: RN
authors.lastname: Hoover
authors.affiliation: Kaiser Permanente Northwest Center for Health Research, Portland, OR.
authors.forename: Andrew
authors.initials: A
authors.lastname: Glass
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Amy
authors.initials: A
authors.lastname: Berrington de Gonzalez
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Mark E
authors.initials: ME
authors.lastname: Sherman
authors.affiliation: National Cancer Institute, Bethesda, MD.
authors.forename: Gretchen L
authors.initials: GL
authors.lastname: Gierach
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D015374:Biosensing Techniques; D000071060:Breast Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D008327:Mammography; D011237:Predictive Value of Tests; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen